11/5
11:23 am
fold
Amicus Therapeutics Q3 2024 Earnings Preview Nov. 05, 2024 11:20 AM ET By: Jaskiran Singh , SA News Editor [Seeking Alpha]
Low
Report
Amicus Therapeutics Q3 2024 Earnings Preview Nov. 05, 2024 11:20 AM ET By: Jaskiran Singh , SA News Editor [Seeking Alpha]
11/4
11:43 am
fold
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know [Yahoo! Finance]
11/1
07:00 am
fold
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
Low
Report
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
10/31
02:04 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
10/28
07:00 am
fold
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
Medium
Report
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
10/23
02:07 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/21
11:44 am
fold
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term [Yahoo! Finance]
10/18
03:52 pm
fold
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold [Seeking Alpha]
Low
Report
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold [Seeking Alpha]
10/18
01:48 pm
fold
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? [Yahoo! Finance]
Low
Report
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? [Yahoo! Finance]
10/18
11:47 am
fold
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
Low
Report
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
10/18
11:47 am
fold
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% [Yahoo! Finance]
Low
Report
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% [Yahoo! Finance]
10/17
01:37 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Bank of America Co. from $13.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at Bank of America Co. from $13.00 to $15.00. They now have a "buy" rating on the stock.
10/17
07:00 am
fold
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
High
Report
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
10/15
02:07 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
10/14
07:37 am
fold
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Is Expected To Breakeven In The Near Future [Yahoo! Finance]
Medium
Report
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Is Expected To Breakeven In The Near Future [Yahoo! Finance]
10/11
12:46 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
10/7
11:05 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/4
07:00 am
fold
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
Low
Report
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
9/20
12:19 pm
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.
Medium
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.
9/17
08:00 am
fold
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
Low
Report
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
9/6
11:09 am
fold
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Low
Report
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
9/6
07:56 am
fold
Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $18.00 price target on the stock.
Low
Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $18.00 price target on the stock.
9/3
07:46 am
fold
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
Low
Report
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
9/3
07:05 am
fold
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
Low
Report
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
9/3
07:00 am
fold
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
Low
Report
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium